Nevertheless, considerable progress has recently been made in the development of KRAS and MYC inhibitors for the treatment of cancer starting to show promising clinical results (Fig. 5), likely bringing the perception of these oncogenes as “undruggable” to an end. Here, KRAS is linked to cancer.